Genetic Guidance in Personal Neurological Treatment. Mini Review

Bartkowiak-Wieczorek, Joanna; Winkler-Galicki, Jakub; Malesza, Ida; Wojtyła-Buciora, Paulina; Mądry, Edyta

doi:10.2478/bgbl-2023-0034

Abstract

Genetic variability (polymorphism) of drug-metabolizing cytochromes determines a diverse response to treatment. Numerous genetic variants of the CYP2D6 cytochrome, which metabolizes the commonly used antidepressant venlafaxine, dictate different therapeutic effects. The implementation of “tailored treatment”, i.e., personalized therapy adjusted to individual needs, remains a dream of the near future.

References

Almazroo, O.A., Miah, M.K., Venkataramanan, R. (2017) ‘Drug Metabolism in the Liver.’ Clin Liver Dis, 21(1), pp. 1-20. 10.1016/j.cld.2016.08.001
Search in Google Scholar Back to article
Baillie, T.A., Rettie, A.E. (2010) ‘Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.’ Drug Metab Pharmacokinet, 26(1), pp. 15-29. doi: 10.2133/dmpk.dmpk-10-rv-089
Search in Google Scholar Back to article
Barras, M., Legg, A. (2017) ‘Drug dosing in obese adults.’ Aust Prescr, 40(5), pp. 189-193. doi: 10.18773/austprescr.2017.053
Search in Google Scholar Back to article
Bartkowiak-Wieczorek, J., Wolski, H., Bogacz, A., Kujawski, R., Ożarowski, M., Majchrzycki, M., Seremak-Mrozikiewicz, A. (2015) ‘Gender-specific implications for pharmacology in childbearing age and in postmenopausal women.’ Ginekol Pol, 86(2), pp. 143-149. doi: 10.17772/gp/2002
Search in Google Scholar Back to article
Berm, E.J., Gout-Zwart, J.J., Luttjeboer, J., Wilffert, B., Postma, M.J. (2016) ‘A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy.’ PLoS One,11(12), e0169065. DOI: 10.1371/journal.pone.0169065
Search in Google Scholar Back to article
Berm, E.J., Hak, E., Postma, M., Boshuisen, M., Breuning, L., Brouwers, J.R., Dhondt, T., Jansen, P.A., Kok, R.M., Maring, J.G., van Marum, R., Mulder, H., Voshaar, R.C., Risselada, A.J., Venema, H., Vleugel, L., Wilffert, B. (2015) ‘Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).’ Trials, pp. 16:37. doi: 10.1186/s13063-015-0561-0
Search in Google Scholar Back to article
J. G. Blanco, P. L. Harrison, W. E. Evans, M. V Relling, “Human cytochrome P450 maximal activities in pediatric versus adult liver,” Drug Metab. Dispos., 2000; 28 (4), s. 379–382.
Search in Google Scholar Back to article
Broly, F., Marez, D., Lo Guidice, J.M., Sabbagh, N., Legrand, M., Boone, P., Meyer, U.A. (1995’ A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency.’ Hum Genet, 196(5), pp. 601-3. doi: 10.2147/PGPM.S181334
Search in Google Scholar Back to article
Butkiewicz, M., Restrepo, N.A., Haines, J.L., Crawford, D.C. (2016) ‘Drug-drug interaction profiles of medication regimens extracted from a de-identified electronic medical records system.’ AMIA Jt Summits Transl Sci Proc, pp. 33-40. PMID: 27570646
Search in Google Scholar Back to article
Doogue, M.P., Polasek, T.M. (2013) ‘The ABCD of clinical pharmacokinetics.’ Ther Adv Drug Saf, 4(1), pp. 5–7. doi: 10.1177/2042098612469335
Search in Google Scholar Back to article
Flegal, K.M., Shepherd, J.A., Looker, A.C., Graubard, B.I., Borrud, L.G., Ogden, C.L., Harris, T.B., Everhart, J.E., Schenker, N. (2009) ‘Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults.’ Am J Clin Nutr, 89(2), pp. 500-8. DOI: 10.3945/ajcn.2008.26847
Search in Google Scholar Back to article
Fogelman, S.M., Schmider, J., Venkatakrishnan, K., von Moltke, L.L., Harmatz, J.S., Shader, R.I., Greenblatt, D. J. ‘O- and N-demethylation of venlafaxine in vitro by human liver micro-somes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.’ Neuropsychopharmacology, 20(5), pp. 480–490. doi: 10.1016/S0893-133X(98)00113-4
Search in Google Scholar Back to article
Freire, A.C., Basit, A.W., Choudhary, R., Piong, C.W., Merchant, H.A. (2011) ‘Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery.’ International Journal of Pharmaceutics, 1-2, pp. 15-28. doi: 10.1016/j.ijpharm.2011.04.069
Search in Google Scholar Back to article
Gaedigk, A., Bradford. L.D., Alander, S.W., Leeder, J.S. (2006) ‘CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.’ Drug Metab Dispos, 34(4), pp. 563-569. doi: 10.1124/dmd.105.008292
Search in Google Scholar Back to article
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., Leeder, J.S. (2016) ‘Prediction of CYP2D6 phenotype from genotype across world populations.’ Genet Med, 19(1), pp. 69-76. doi: 10.1038/gim.2016.80
Search in Google Scholar Back to article
Golden, R.N., Nicholas, L. (2000) ‘Antidepressant efficacy of venlafaxine.’ Depress Anxiety, 12 Suppl 1, pp. 45-49. doi: 10.1002/1520-6394(2000)12:1+<;45::AID-DA5>3.0.CO;2-5
Search in Google Scholar Back to article
Grasmader, K., Verwohlt, P.L., Rietschel, M. Dragicevic, A., Müller, M., Hiemke, C., Freymann, N., Zobel, A., Maier, W., Rao, M.L (2004) ‘Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.‘ Eur J. Clin. Pharmacol, 60(5), pp. 329–336. doi: 10.1111/j. 1365-2125.2007.03052.x
Search in Google Scholar Back to article
Holford, N. (2015) ‘Clinical pharmacology = disease progression + drug action.’ TBr J Clin Pharmacol, 79(1), pp. 8-27. doi: 10.1111/bcp.12170
Search in Google Scholar Back to article
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c3f8268-ef43-d58c-7da6-dd44f-8feb3be.
Search in Google Scholar Back to article
http://www.cypalleles.ki.se/5.
Search in Google Scholar Back to article
https://cpicpgx.org/resources/term-standardization/.
Search in Google Scholar Back to article
https://www.drugbank.ca/drugs/DB00285.
Search in Google Scholar Back to article
https://www.pharmvar.org/gene/CYP2D6
Search in Google Scholar Back to article
Jiang, F., Kim, H.D., Na, H.S., Lee, S.Y., Seo, D.W., Choi, J.Y., Ha, J.H., Shin, H.J., Kim, YH, Chung MW. (2015) ‘The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.’ Psychopharmacology (Berl), 232(11), pp. 1899-1909. doi: 10.1007/s00213-014-3825-6
Search in Google Scholar Back to article
Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient’s perspective. Ther Clin Risk Manag. 2008;4(1):269-86. doi: 10.2147/tcrm.s1458
Search in Google Scholar Back to article
Johnson E.M., Whyte E., Mulsant B.H., Pollock B.G., Weber, E., Begley, A.E., Reynolds, C.F. (2006) ‘Cardiovascular changes associated with venlafaxine in the treatment of late-life depression.’ Am J Geriatr Psychiatry, 14(9), pp. 796–802. doi: 10.1097/01.JGP.0000204328.50105.b3
Search in Google Scholar Back to article
Karki, R., Pandya, D., Elston, R.C., Ferlini, C. (2015) ‘Defining “mutation” and “polymorphism” in the era of personal genomics.’ BMC Med Genomics, 8, pp. 37. doi.org/10.1186/s12920-015-0115-z
Search in Google Scholar Back to article
Karlsson, L., Schmitt, U., Josefsson, M., Carlsson, B., Ahlner, J., Bengtsson, F., Kugelberg, F.C., Hiemke, C. (2010) ‘Blood–brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking Pglycoprotein.’ Eur Neuropsychopharmacol, 20, pp. 632–640. doi: 10.1016/j.euroneuro.2010.04.004
Search in Google Scholar Back to article
Kimura, S., Umeno, M., Skoda, RC., Meyer, UA., Gonzalez, F.J. (1989) ‘The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.’ Am J Hum Genet, 45(6), pp. 889-904. PMID: 2574001; PMCID: PMC1683468.
Search in Google Scholar Back to article
Kirchheiner, J., Nickchen, K., Bauer, M. Wong, M.L., Licinio, J., Roots, I., Brockmöller, J. (2004) ‘Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.’ Mol. Psychiatry, 9(5), pp. 442–473. doi: 10.1038/sj.mp.4001494
Search in Google Scholar Back to article
Ku, L.C., Smith, P.B. (2014) ‘Dosing in neonates: special considerations in physiology and trial design.’ Pediatr Res. 77(1-1), pp. 2-9. doi: 10.1038/pr.2014.143.
Search in Google Scholar Back to article
Lobello, K.W., Preskorn, S.H., Guico-Pabia, C.J., Jiang, Q., Paul, J., Nichols, A.I., Patroneva, A., Ninan, P.T. (2010) ‘Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.’ J Clin Psychiatry, 711, pp. 482–1487. doi: 10.4088/JCP.08m04773blu
Search in Google Scholar Back to article
Mackenzie, P.I., Somogyi, A.A., Miners, J.O. (2017) ‘Advances in drug metabolism and pharmacogenetics research in Australia.’ Pharmacol Res, 116, pp. 7-19. doi: 10.1016/j.phrs.2016.12.008
Search in Google Scholar Back to article
Magalhães, P., Alves, G., Llerena, A., Falcão, A. (2015) ‘Clinical drug-drug interactions: focus on venlafaxine.’ Drug Metab Pers Ther, 30(1), pp. 3-17. doi: 10.1515/dmdi-2014-0011
Search in Google Scholar Back to article
Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J.M., Spire, C., Lafitte, J.J., Meyer, U.A., Broly, F. (1997) ‘Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.’ Pharmacogenetics, 7(3): pp. 193-202.doi: 10.1097/00008571-199706000-00004
Search in Google Scholar Back to article
McGraw, J., Waller, D. (2012) ‘Cytochrome P450 variations in different ethnic populations.’ Expert Opin Drug Metab Toxicol, 8(3), pp. 371-82. doi: 10.1517/17425255.2012.657626
Search in Google Scholar Back to article
Ng, C., Sarris, J., Singh, A. Bousman, C,. Byron, K., Peh, L.H., Smith, D.J., Tan, C.H., Schweitzer, I. (2013) ‘Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.’ Hum. Psychopharmacol, 28(5), pp. 516–522. doi: 10.1002/hup.2340
Search in Google Scholar Back to article
Preissner, S.C., Hoffmann, M.F., Preissner, R., Dunkel, M., Gewiess, A., Preissner, S. (2013) ‘Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.’ PLoS One, 8(12):e82562. doi: 10.1371/journal.pone.0082562
Search in Google Scholar Back to article
Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.U., Schwab, M., Zanger, U.M. (2000) ‘Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6.’ Pharmacogenetics, 10(7), pp. 577-581. DOI: 10.1097/00008571-200010000-00001
Search in Google Scholar Back to article
Roden, D.M., Wilke, R.A., Kroemer, H.K., Stein, C.M. (2011) ‘Pharmacogenomics: the genetics of variable drug responses.’ Circulation, 123(15), pp.1661-1670. doi: 10.1161/CIRCULATIONAHA.109.914820
Search in Google Scholar Back to article
Rolla, R., Gramaglia, C., Dalo, V., Ressico, F., Prosperini, P., Vidali, M., Meola, S., Pollarolo, P., Bellomo, G., Torre, E., Zeppegno, P. (2014) ‘An observational study of Venlafaxine and CYP2D6 in clinical practice.’ Clin. Lab, 60(2), pp. 225–231. doi: 10.7754/clin.lab.2013.130141
Search in Google Scholar Back to article
Sacristán, J.A., Avendaño-Solá, C. (2015) ‘On heterogeneity of treatment effects and clinical freedom.’ Int J Clin Pract, 69(1), pp. 6-8. doi: 10.1111/ijcp.12537
Search in Google Scholar Back to article
Shams, M.E., Arneth, B., Hiemke, C., Dragicevic, A., Müller, M.J., Kaiser, R., Lackner, K., Härtter, S. (2006) ‘CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.’ Journal of clinical pharmacy and therapeutics, 31(5), pp. 493–502. DOI: 10.1111/j.1365-2710.2006.00763.x
Search in Google Scholar Back to article
Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, K. (2001) ‘dbSNP: the NCBI database of genetic variation.’ Nucleic Acids Res, 1;29(1), pp. 308-311. doi: 10.1093/nar/29.1.308
Search in Google Scholar Back to article
Steen, V.M., Molven, A., Aarskog, N.K., Gulbrandsen, A.K. (1995) ‘Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene.’ Hum Mol Genet, 4(12), pp. 2251-7. doi: 10.1093/hmg/4.12.2251
Search in Google Scholar Back to article
Taranu, A., Colle, R., Gressier, F., El Asmar, K., Becquemont, L., Corruble, E., Verstuyft, C. (2017) ‘Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings’ Pharmacogenomics, 18(7), pp. 639-650. doi: 10.2217/pgs-2017-0003
Search in Google Scholar Back to article
Thase, M.E. (2006) ‘Treatment of anxiety disorders with venlafaxine XR.’ Expert Rev Neurother, 6(3), pp. 269-82. doi: 10.1586/14737175.6.3.269
Search in Google Scholar Back to article
van den Anker, J., Allegaert, K. (2012) ‘Clinical pharmacology in neonates and young infants: the benefit of a population-tailored approach.’ Expert Rev Clin Pharmacol. 5(1), pp. 5-8. doi: 10.1586/ecp.11.65
Search in Google Scholar Back to article
Wellington, K., Perry, C.M.T. (2001) ‘Venlafaxine extended-release: a review of its use in the management of major depression.’ CNS Drugs, 15(8), pp. 643-669. doi: 10.2165/00023210-200115080-00007
Search in Google Scholar Back to article
Xu, J., Mercury J, Zhang, Z., Xu, F. (2008) ‘Psychological, social and behavioural factors that influence drug efficacy: a noteworthy research subject in clinical pharmacology.’ Br J Clin Pharmacol, 66(6), pp. 901-902. doi: 10.1111/j.1365-2125.2008.03300.x
Search in Google Scholar Back to article

Genetic Guidance in Personal Neurological Treatment. Mini Review

Abstract

Paradigm

My account